Effect of vitamin D supplementation on primary hypertension: a randomized clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201211239014N12

Enrollment

208

Registered

2012-12-01

Start date

2012-12-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary hypertension. Essential (primary) hypertension

Interventions

Intervention 1: Routine anti-hypertension medication plus oral soft gel of vitamin D supplementation (D3) 50,000 U one per week for three months. Intervention 2: Routine anti-hypertension medication f

Treatment - Drugs

Routine anti-hypertension medication plus oral soft gel of vitamin D supplementation (D3) 50,000 U one per week for three months

Routine anti-hypertension medication for three months

Eligibility

Sex/Gender

All

Age

18 Years to 149 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: (a) age of 15 or greater; (b) having systolic blood pressure equal to or greater than 140 mmHg or diastolic blood pressure equal to or greater than 90 mmHg on two separate occasions. Exclusion criteria: (a) having secondary hypertension; (b) having diabetes; (c) having chronic kidney disease; (d) being pregnant; (e) history of using of vitamin D or calcium during the last three months; (f) history of using Thiazide-type diuretics.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Systolic blood pressure in mmHg. Timepoint: at baseline and monthly for three months. Method of measurement: Using mercury manometer and a stethoscope in setting position from right hand.;Diastolic blood pressure in mmHg. Timepoint: at baseline and monthly for three months. Method of measurement: Using mercury manometer and a stethoscope in setting position from right hand.	—

Secondary

Measure	Time frame
Systemic adverse effect such as vomoting. Timepoint: Monthly for three months. Method of measurement: Through question.;?ystemic adverse effect such as nausea. Timepoint: Monthly for three months. Method of measurement: Through question.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Jalal Poorolajal

Research Center for Health Sciences and Department of Epidemiology & Biostatistics

poorolajal@umsha.ac.ir+98 81 1838 0090

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026